Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

By J. Colombel, R. Panaccione, P. Bossuyt, M. Lukáš, F. Baert, T. Vaňásek, A. Danalıoğlu, G. Novacek, A. Armuzzi, X. Hébuterne and 16 more. The Lancet, 2017

756 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/307983dcdddbf7fb5d7c41fe53b92bf17baeccbd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Colombel
2. L. Peyrin-Biroulet
3. W. Sandborn

In Genetics

1. J. Colombel
2. W. Sandborn
3. L. Peyrin-Biroulet
4. Bruce E. Sands
5. M. Abreu
6. Markus F. Neurath

In Surgery

1. M. Abreu
2. J. Schölmerich

Citations in the corpus

• The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. (2020, background): “17 Using this strategy enhanced mucosal endoscopic healing compared with reliance on symptoms alone to guide treatment.”
• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. (2020, background): “5 On the other hand, and not surprisingly, patients identify clinical symptoms as the most important parameters to treat.”
• ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. (2019, methodology): “16 researched literature was conducted according to the Oxford methodology (Oxford Centre for Evidence-Based Medicine: the Oxford 2011 Levels of Evidence 2—grading from evidence level [EL] 1: systematic review of randomised controlled trials to EL 5: expert opinion).”